ZARZA We are Zarza, the prestigious firm behind major projects in information technology.
Listen "Glofitamab & TALAPRO - 2"
Episode Synopsis
This week's Pod looks at the 2nd CD20-CD3 bispecific T-Cell engager approved this year (or at all), glofitamab, and the TALAPRO-2 study of combining talazoparib to enzalutaimide.
TALAPRO-2: https://doi.org/10.1016/S0140-6736(23)01055-3
TALAPRO-2: https://doi.org/10.1016/S0140-6736(23)01055-3
More episodes of the podcast OncoPharm
Bladder Cancer Updates & SC Amivantamab
18/12/2025
ASH 2025
11/12/2025
DPYD Deficiency Testing
04/12/2025
Cornucopia of Autumn Updates
26/11/2025
PGYNone: Dandelion Effect
20/11/2025
PGY1 Pathway: Road Trip!
13/11/2025
PGY2 Pathway: A Planned City
06/11/2025
Tale from the Crypt: Belantamab Mafodotin
30/10/2025
ESMO 2025
23/10/2025
IL-2
16/10/2025
In God we trust